SCHEMBL1496733

SCHEMBL1496733

COc1ccccc1OCC(C)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
CYP1A2 P05177 2/20 0.68
AGTR1 P30556 1/20 0.68
SMN1; SMN2 Q16637 2/20 0.58
KDM4E B2RXH2 2/20 0.58
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
POLB P06746 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.49
IDO1 P14902 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
MAPT P10636 1/20 0.47
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11303021 0.92 LMNA (0.65) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL29941729 0.86 LMNA (0.82) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL2328960 0.86 LMNA (0.82) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL27251161 0.84 ALOX15 (0.62) LMNACYP1A2AGTR1KDM4EL3MBTL1
SCHEMBL1446334 0.83 LMNA (0.61) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL15658611 0.83 LMNA (0.49) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL3308807 0.82 LMNA (0.66) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
SCHEMBL10263938 0.82 LMNA (0.55) LMNACYP1A2AGTR1KDM4EPOLB
SCHEMBL10636086 0.82 LMNA (0.47) LMNACYP1A2AGTR1SMN1; SMN2KDM4E
Guaifenesin SCHEMBL31161209 0.81 CYP1A2 (1.00) LMNACYP1A2AGTR1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114848640-B Application of compound in preparation of anti-inflammatory drugs 山东第一医科大学(山东省医学科学院) 2023-04-07 CN claimed
CN-114848640-A Application of compound in preparation of anti-inflammatory drugs 山东第一医科大学(山东省医学科学院) 2022-08-05 CN claimed
CN-119998412-A Ink composition, layer using the same, and electrophoretic device and display device including the layer 三星显示有限公司 2025-05-13 CN disclosed
WO-2024182479-A2 COMPOUNDS AND METHODS OF TREATING OR PREVENTING A BACTERIAL INFECTION IN A PLANT OHIO STATE INNOVATION FOUNDATION (US) 2024-09-06 WO disclosed
US-20240093042-A1 INK COMPOSITION, LAYER USING THE SAME, ELECTROPHORESIS DEVICE AND DISPLAY DEVICE COMPRISING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-03-21 US disclosed
CN-115385847-B Polysubstituted diaryl compound, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2023-09-29 CN disclosed
CN-114848640-B Application of compound in preparation of anti-inflammatory drugs 山东第一医科大学(山东省医学科学院) 2023-04-07 CN disclosed
CN-115385847-A Polysubstituted diaryl compound and preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2022-11-25 CN disclosed
CN-113387873-B Substituted diaryl compound, preparation method and application thereof 山东第一医科大学(山东省医学科学院) 2022-09-20 CN disclosed
CN-114848640-A Application of compound in preparation of anti-inflammatory drugs 山东第一医科大学(山东省医学科学院) 2022-08-05 CN disclosed
US-7906667-B2 Method for producing optically active alcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-03-15 US disclosed
EP-1178973-B1 PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2005-12-21 EP disclosed
US-20040242554-A1 CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION 2004-12-02 US disclosed
US-20030092694-A1 Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION 2003-05-15 US disclosed
US-6465467-B1 DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS BIOVITRUM AB (SE) 2002-10-15 US disclosed
EP-1178973-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION Pharmacia AB (SE) 2002-02-13 EP disclosed
WO-2000076984-A2 NOVEL COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2000-12-21 WO disclosed
EP-0143381-B1 BIPHENYLYLALKANOIC ACID DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM Dr. L. ZAMBELETTI S.p.A. (IT) 1988-03-09 EP disclosed
US-4570013-A ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY AGENTS; METHOXYPHENOXYPROPANOL ESTERS DR. L. ZAMBELETTI S.P.A. (IT) 1986-02-11 US disclosed
EP-0143381-A2 Biphenylylalkanoic acid derivatives, methods of preparation and pharmaceutical compositions therefrom Dr. L. ZAMBELETTI S.p.A. (IT) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092694-A1 Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases HTR2C, HTR3C, HTR2A LMNA 2553/4885CYP1A2 159/4885AGTR1 284/4885
US-20040242554-A1 CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES HTR2C, HTR3C, HTR2A LMNA 2654/4885CYP1A2 157/4885AGTR1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.